This thesis includes phase I clinical and pharmacological studies on second
and third generation topoisomerase I inhibitors, either administered orally,
or intravenously as a macromolecular drug-delivery system, and on the antimicrotubulin
agent, paclitaxel encapsulated in liposomes, to investigate the
suitability of prolonged exposure of these anti-cancer agents and formulations.
These studies were performed since in preclinical models, the cytotoxicity
of both topoisomerase I inhibitors and paclitaxel increases with duration of
exposur
